Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

ABSTRACT:

Background

Risankizumab has demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis in randomized clinical trials.

Objectives

To evaluate safety data from risankizumab psoriasis phase I-III clinical trials.

Methods

Short-term safety (through week 16) was analysed using integrated data from five phase II and III clinical trials. Long-term safety was evaluated using integrated data from 17 phase I-III completed and ongoing trials.

Results

Short-term safety analyses included 1306 patients receiving risankizumab 150 mg and 300 patients receiving placebo [402·2 and 92·0 patient-years (PY) of exposure, respectively]. Long-term analyses included 3072 risankizumab-treated patients (exposure: 7927 PY). The median (excluding four outliers) t

SUBMITTER: Gordon KB 

PROVIDER: S-EPMC9298814 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature